Travere Therapeutics to Report Second Quarter 2022 Financial Results
July 28, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the...
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
June 02, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday,...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2021, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
February 02, 2021 07:00 ET
|
Travere Therapeutics, Inc.
Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally...